Member Info for Muck165

If the funder is going to be taking part equity then given the amounts involved and our current SP I think there is a fair chance they will end up with a majority stake. If that were the case, it might explain AP's comment that they would pay a premium to the price for it "on the day".

I have wondered as well if the placing was done (in part) to reduce the price for the benefit of the incoming funder. Complete supposition I know.

Personally I am hoping for news one way or the other by next Friday when the 2nd tranche due to Alpha would be due. As I have said before, that's also the day the second tranche of placing shares hits the market and AP does tend to have a record of releasing news or manipulating events to suit him.

Just idle thoughts....

Well, as per the link below they definitely reported a reduction from 0.84 to 0.35 yesterday and my bet is they got out entirely today.

Decent article from our Nina Garrett in FemTech world yesterday.

Could possibly give a clue on other things we might be working on, or perhaps be an indicator that we might hear something re Hormona soon. Or, it could just be an article!

https://www.femtechworld.co.uk/insight/18149-abi23/

Well good luck - gotta make right decisions for you.

Wasn’t it some unknown called Buffet who said something like “the stock market is a device for transferring money from the impatient to the patient”

Don’t expect he was very successful…

All shorts now closed by GSA

https://shorttracker.co.uk/company/GB00BQ7WTT20/

Don’t think anyone has highlighted that GSA reduced their short position on Weds from 1.29% to 0.84%.

This again relates to Regulatory changes but to be honest is one of the better I have read from ABDX and clearly shows, I think, why the company is placing so much focus on the regulatory support aspects of its business. Fundamentally, unless you are a large player with many products then outsourcing all of the regulatory stuff to a company like us seems a much better strategic option in the new environment. And lets face it, the companies we deal with are developers, normally run by scientists. - they are unlikely I think to have the resource or inclination to navigate all the regulatory hurdles and requirements and, more importantly, they will not want to slip up and delay, or potentially waste, years of development work.

https://www.abingdonhealth.com/ivdd-to-ivdr-transition-for-lateral-flow-tests/

Looks like Salignostics are taking their saliva technology into the cancer testing space.

https://www.linkedin.com/posts/arc-innovation-center-at-sheba_sheba-medical-center-salignostics-to-develop-activity-7201465657391988736-RI4l?utm_source=share&utm_medium=member_desktop

Nothing to indicate that this will be in the form of an LFT but it could be, and Yates has reacted to the post. It will be a while in development anyway.

Just a question, but is it a coincidence that the next (and much larger) tranche of placing shares are due to hit the market on the same day as the second debt payment is due? Am just always suspicious about how AP times everything to suit his needs.

Https://www.londonstockexchange.com/news-article/MMM/conditional-fundraise-of-ps5m-completed/16489429

And you have posted this some message on 28 other boards. Reported.

We’ve been saying on here for a while that part of the ABDX allure is the move towards decentralised health care and, with it, the need for home testing.

Seems the FDA likes the idea too, having now launched its Home as a Health Care Hub initiative.

The future of healthcare will, imo, look very different to what it is today, and ABDX are very well positioned to take advantage.

https://www.fda.gov/medical-devices/medical-devices-news-and-events/fda-launches-health-care-home-initiative-help-advance-health-equity?utm_source=FDALinkedin

I’ve been reading more and more about Bird Flu concerns, particularly in the US.

Here is the latest example

https://www.bbc.co.uk/news/articles/clee5685w19o

Interesting then that our Liam Currivan put this post out today

https://www.linkedin.com/posts/liam-currivan-8bab88135_could-the-avian-flu-be-our-next-pandemic-activity-7199325420444413952-nPrF?utm_source=share&utm_medium=member_desktop

So, he says“ Perhaps we need a #lateralflow rapid antigen test to be developed for infection monitoring...”.

I wonder, is that a hint that we might already be working on one for a customer?

To clarify, discussions are with the owner of the Swiss company, not with the Company, and every RNS relating to it suggests it will be they, and not the company investing.

How long does it take to transfer money again?. “Shortly”, the most missed word in AIM company statements, closely followed by “imminently”

Two little thing I did notice in the video;

- Each LVOne test actually comprises 2 LFT’s.

- They confirmed that their manufacturing partner, “based in York” has already made 20,000 “tests”, so 40,000 individual LFT’s.

So if this gets off the ground, and every indication is it will, then the manufacturing requirement will actually be double the “tests” sold.

Upfront posted this video to explain their history, product, and long collaboration with North East hospitals. 20 mins and worth a watch

https://www.youtube.com/watch?v=Tv1ls6QasiY

Well, the only new comment I can see is; “ Our next objective is to commence deliveries to our inaugural customers this summer.”

“Deliveries” might suggest they already have orders, and that would mean manufacturing by us.

Interesting to see they’ve only just put something out on this given they got UKCA in March!

Pleasure! So many good things to keep an eye on here.

FOFH still puzzles me though. It (nor Devyn) has any web presence as far as I can see and whilst STI diagnostics is a great market to be in because rates across a variety of infections and age groups are rising globally, “investing” £500k in a new (and what appears to be) one man band venture seems bizarre unless there is an angle somewhere. Just can’t think of the angle, unless it has something to do with our rights to offer the tests as own brand perhaps with Boots in mind, or wanting a US foothold.

Our investment would value FOFH at over £2m, being about 14 of our current MCAP. On the face of it that would seem foolish at this pre reg approval/commercialisation stage unless there is a nugget somewhere.

And Yates has never struck me as foolish.

The only other reason I can think of is that FOFH couldn’t pay us, so we took equity instead. But if that were the case I would have hoped for more than 23%.

Anyway, current things on my radar are outcomes from the latest Upfront and Loop funding rounds, Upfront UKCA approval, and of course the early July trading update.

Nice post from 52 North, and so is the comment from the National Clinical Lead for Innovation at NHS England.

https://www.linkedin.com/posts/52north_spotlight-on-the-nhs-clinical-entrepreneur-activity-7198268800885026816-XGf3?utm_source=share&utm_medium=member_desktop